Summit Therapeutics

Summit Therapeutics (operating at smmttx.com) is a biopharmaceutical oncology company specializing in the discovery, development, and commercialization of innovative cancer treatments. Founded in 2003 and headquartered in Miami, Florida, the company focuses on addressing unmet needs in oncology by advancing targeted therapies designed to improve patient outcomes. Its pipeline includes promising candidates like ivonescimab, which has already treated over 4,000 patients globally across clinical trials. By leveraging cutting-edge biotechnology and precision medicine, Summit Therapeutics develops treatments tailored to specific cancer subtypes, offering physicians and caregivers more effective options. The company’s approach combines rigorous clinical research with a commitment to accelerating drug approvals, ensuring therapies reach patients faster. Backed by a $500 million private placement in 2025—including significant investments from insiders and leading financial partners—Summit Therapeutics continues to expand its operational footprint while driving progress in oncology.